NASDAQ:ADAG Adagene (ADAG) Stock Price, News & Analysis $1.76 -0.25 (-12.44%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$1.76 -0.01 (-0.28%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Adagene Stock (NASDAQ:ADAG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Adagene alerts:Sign Up Key Stats Today's Range$1.35▼$2.0550-Day Range$1.48▼$3.3752-Week Range$1.27▼$4.85Volume1.37 million shsAverage Volume426,558 shsMarket Capitalization$116.25 millionP/E RatioN/ADividend YieldN/APrice Target$8.25Consensus RatingModerate Buy Company Overview Adagene Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based cancer immunotherapies. Its research combines computational protein-design methods with antibody engineering to create treatments intended to target tumors and engage the immune system. The company’s technologies include its SAFEbody platform, which is designed to keep an antibody’s activity masked until it reaches the tumor environment. Adagene is also developing antibody candidates that target immune-regulatory pathways, including CTLA-4, for potential use in cancer treatment. Founded in 2011, Adagene has operations in China and the United States and pursues drug development for international markets. Co-founder Peter Luo has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Adagene Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreADAG MarketRank™: 3.12210850974 of 5 starsAdagene scored higher than 62% of companies evaluated by MarketBeat, and ranked 289th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingAdagene has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAdagene has a consensus price target of $8.25, representing about 368.8% upside from its current price of $1.76.Amount of Analyst CoverageAdagene has only been the subject of 3 research reports in the past 90 days.Read more about Adagene's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Adagene are expected to grow in the coming year, from ($0.50) to ($0.45) per share.Price to Book Value per Share RatioAdagene has a P/B Ratio of 2.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.18% of the float of Adagene has been sold short.Short Interest Ratio / Days to CoverAdagene has a short interest ratio ("days to cover") of 11.83, which indicates bearish sentiment.Change versus previous monthShort interest in Adagene has recently increased by 2.70%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdagene does not currently pay a dividend.Dividend GrowthAdagene does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.43 News SentimentAdagene has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Adagene this week, compared to 2 articles on an average week. Company Ownership4.4 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Adagene in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $69,914.00 in company stock, which represents 0.0601% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Adagene insiders have bought more of their company's stock than they have sold. Specifically, they have bought $69,914.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders21.20% of the stock of Adagene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions9.51% of the stock of Adagene is held by institutions.Read more about Adagene's insider trading history. Receive ADAG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adagene and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADAG Stock News HeadlinesWall Street Zen Upgrades Adagene (NASDAQ:ADAG) to "Hold"November 21 at 4:07 AM | americanbankingnews.comAdagene Inc. Announces First Patient Dosed In Phase 1 Study Of ADG138, A Novel HER2 CD3 Double-Masked Bispecific T-Cell EngagerNovember 19 at 1:01 PM | marketscreener.comMPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access for just $7. The specialized indicator shows when a stock is likely to "snap back," helping traders avoid buying at the peak. It can also flag when a stock may bounce off the bottom so you can time your entry. Run NVDA or any other popular AI stock through it before you place a trade.November 22 at 1:00 AM | Base Camp Trading (Ad)Adagene Announces First Patient Dosed in Phase 1 Study of ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell EngagerNovember 19 at 7:00 AM | globenewswire.comAdagene Inc. and City of Hope Open Clinical Trial to Test New Therapy for Patients with Hard-To-Treat Colorectal CancerNovember 17, 2026 | marketscreener.comMAdagene and City of Hope Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal CancerNovember 17, 2026 | markets.businessinsider.comAdagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable ...November 9, 2026 | markets.businessinsider.comAdagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal CancerNovember 9, 2026 | globenewswire.comSee More Headlines ADAG Stock Analysis - Frequently Asked Questions How have ADAG shares performed this year? Adagene's stock was trading at $1.89 on January 1st, 2026. Since then, ADAG stock has decreased by 6.9% and is now trading at $1.76. How were Adagene's earnings last quarter? Adagene Inc. Sponsored ADR (NASDAQ:ADAG) issued its quarterly earnings results on Wednesday, April, 1st. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.28) by $0.24. The company earned $3.84 million during the quarter, compared to analysts' expectations of $17.50 million. When did Adagene IPO? Adagene (ADAG) raised $132 million in an IPO on Tuesday, February 9th 2021. The company issued 7,354,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs (Asia), Morgan Stanley and Jefferies acted as the underwriters for the IPO and China Renaissance was co-manager. Who are Adagene's major shareholders? Top institutional shareholders of Adagene include Flputnam Investment Management Co. (1.03%), Marshall Wace LLP (0.68%) and State Street Corp (0.04%). Insiders that own company stock include Peter Luo and Man Kin Tam. View institutional ownership trends. How do I buy shares of Adagene? Shares of ADAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adagene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adagene investors own include Advanced Micro Devices (AMD), Plug Power (PLUG), Skillz (FIRY), NIO (NIO), Allogene Therapeutics (ALLO), Blink Charging (BLNK) and CRISPR Therapeutics (CRSP). Company Calendar Today11/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 3 weeks, ADAG's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ADAG CIK1818838 Webwww.adagene.com Phone86-512-8777-3632FaxN/AEmployees128Year Founded2012Price Target and Rating Average Price Target for Adagene$8.25 High Price Target$10.00 Low Price Target$7.00 Potential Upside/Downside+368.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.01 Current Ratio5.02 Quick RatioN/A Sales & Book Value Annual Sales$9.29 million Price / Sales12.51 Cash FlowN/A Price / Cash FlowN/A Book Value$0.75 per share Price / Book2.35Miscellaneous Outstanding Shares66,052,000Free Float52,049,000Market Cap$116.25 million OptionableNot Optionable Beta0.69 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ADAG) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredGold Miners Post Record Cash Flows as AI Stocks WobbleGold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredNoah’s Ark found?Scientists may have discovered Noah's Ark buried under a mountain in eastern Turkey, just two miles from the I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagene With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.